复方双氢青蒿素片治疗输入性疟疾患者的临床疗效观察

Clinical observation on the effect of compound dihydroartemisinin on the treatment of the patients with imported malaria

目的研究输入性疟疾患者采用复方双氢青蒿素片治疗疗效。方法随机选取2012年1月～2016年1月124例输入性疟疾患者纳入本次研究，其中对照组采用复方磷酸萘酚喹片治疗；观察组采用复方双氢青蒿素片治疗。评价2组临床疗效，记录2组患者平均退热时间和原虫转阴时间，统计治疗期间不良反应。结果观察组临床治愈率、复燃率分别为98.39%（61/62）、1.61%（1/62）与对照组96.77%（60/62）、2.23%（2/62）比较，差异无统计学意义；观察组平均退热时间和原虫转阴时间分别为（26.2±9.2）h、（47.9±18.8）h与对照组（27.3±8.8）h、（48.6±19.3）h比较，差异无统计学意义。观察组不良反应率2.23%（2/62），明显低于对照组16.13%（10/62）（χ2=35.71，P=0.00）。结论临床应用复方双氢青蒿素片与复方磷酸萘酚喹片治疗输入性疟疾均可取得较好效果，但前者不良反应更少，因此患者易耐受，值得作为输入性疟疾患者首选治疗方案。

Objective To study the effect of compound dihydroartemisinin on the treatment of the patients with imported malaria.Methods A randomized selection of124cases with imported malaria from January2012to January2016was included in the study.The control group were treated with compound naphthyl phosphate quinoline.The observation group were treated with compound dihydroartemisinin tablets.The clinical effect in the two groups was evaluated.The mean time of fever and the duration of the parasite were recorded.The adverse reactions were observed and recorded.Results The clinical cure rate and recovery rate were98.39%(61/62)and1.61%(1/62)in the observation group,and96.77%(60/62)and2.23%(2/62)in the control group,the difference in the two groups were no statistically significant.The mean antipyretic time and parasite clearance time were(26.2±9.2)h,(47.9±18.8)h respectively in the observation group,and(27.3±8.8)h,(48.6±19.3)h respectively in the control group the difference in the two groups were no statistically significant.The adverse reaction rate was2.23%(2/62)in the observation group,which was significantly lower than that in the control group(16.13%,10/62,χ2=35.71,P=0.00).Conclusion Compound dihydroartemisinin tablets and compound naphthoquine phosphate tablets can achieve good results in the treatment of imported malaria,but the former has less adverse reactions,so the patients are easy to tolerate and deserve to be treated as the preferred treatment for imported malaria patients.